Reducing Life-threatening and Disabling Hemorrhagic Conditions

Our patented technology aims to address unmet medical needs by using an innovative mechanism of action to inhibit fibrinolysis.

virus sample

MECHANISM OF ACTION

A Novel Antifibrinolytic Strategy

Explore MOA Details

blood analysis

UNMET MEDICAL NEEDS

Life-threatening Hemorrhages

Explore Unmet Needs

Hand of doctor holding blood test tubes during covid-19 outbreak

THE EVIDENCE

89% Reduced Bleeding Time in Preclinical In-vivo Animal Models

Explore Study Findings

A Novel Antifibrinolytic Strategy

Hemostatics is developing CM-352, a novel antifibrinolytic agent to reduce bleeding in life-threatening and disabling hemorrhagic conditions.
With a new mechanism of action to inhibit fibrinolysis, our patented preclinical candidate is addressing significant unmet medical needs (e.g. IntraCranial Hemorrhage where other treatments are still suboptimal).

CM-352 by Hemostatics

A Novel Antifibrinolytic Strategy

Hemostatics is developing CM-352, a novel antifibrinolytic agent to reduce bleeding in life-threatening and disabling hemorrhagic conditions.
With a new mechanism of action to inhibit fibrinolysis, our patented preclinical candidate is addressing significant unmet medical needs (e.g. IntraCranial Hemorrhage where other treatments are still suboptimal).

Targeted Conditions

logo surgery

Surgery

Major Surgeries

Significant blood loss occurs in 3% of the 100-120 millions of major surgeries every year in the 7 major markets. Cardiac surgery is the largest consumer of blood transfusion products.

Explore Surgery

traumatology

Trauma

Trauma

Hemorrhage is responsible of 45% of deaths occurring within 24h after traumatic injury.

Explore Trauma

logo ich

ICH

IntraCerebral Hemorrhage

IntraCerebral Hemorrhage (ICH) accounts for approx. 20% of all strokes, with a case fatality rate of 54% at 1 year. There is currently no treatment to stop hemorrhage or prevent hemorrhage enlargement.

Explore ICH

gynecology logo

Gynecology

GYNECOLOGY

Several gynecological conditions are caused by an excess of bleeding (Heavy Menstrual Bleeding, Postpartum Bleeding, Cesaren, etc.).

Explore Gynecology

disorders logo

RARE DISEASES

RARE DISEASES

Several Bleeding Disorders are associated with hemorrhage (Hereditary Angioedema, Hemophilia, etc.).

Explore Rare Diseases

Bleeding logo

GI BLEEDING

GASTROINTESTINAL BLEEDING

Acute gastrointestinal (GI) bleeding is a potentially life-threatening emergency and common cause of hospitalization.

Explore GI Bleeding

We Partner With Leading Experts in the Fields of Science, Healthcare, and Business

Centro de investigación medica aplicada - universidad de navarra
Healthech 180
Fundacion par la investigacion medica aplicada
Sociedad Espanola de Trombosis y Hemostasia

Exceptional Accomplishments Power the Holistic Success of Hemostatics

patent

4

PATENTS
Strong IP position: 3 patents on novel drug formulas and 1 patent protecting the mechanism against known inhibitors repositioning.

time logo red

89%

BLEEDING TIME DECREASE
CM-352 reduces Bleeding Time in mice by 89%.

blood

61%

BLOOD LOSS DECREASE
CM-352 reduces Blood Loss by 61% in a Tail Bleeding mice model.

preclinical test

4

PRECLINICAL MODELS
Efficacious in 4 different preclinical animal models of bleeding. Optimal profile for i.v. administration, ideal for short term control of bleeding.

Want To Start Investing With Us?

Investing in the novel biopharmaceutical technology of Hemostatics can help accelerating the development of innovative solutions addressing potentially life-threatening hemorrhagic conditions.